Home
ADIL
ADIL News

Latest Adial Pharmaceuticals Inc (ADIL) News on August 10, 2025

Adial Pharmaceuticals Secures U.S.-Based Manufacturing Through Agreements with Cambrex and Thermo Fisher Scientific for Drug Substance and Drug Product Supply

GlobeNewswire

2 months ago

Adial Pharmaceuticals Secures U.S.-Based Manufacturing Through Agreements with Cambrex and Thermo Fisher Scientific for Drug Substance and Drug Product Supply

MT Newswires

2 months ago

Top Midday Decliners

Adial Pharmaceuticals Announces Pricing of $3.6 Million Public Offering

GlobeNewswire

2 months ago

Adial Pharmaceuticals Announces Pricing of $3.6 Million Public Offering

Adial Pharmaceuticals Submits Briefing Package to Guide Upcoming FDA Meeting

GlobeNewswire

2 months ago

Adial Pharmaceuticals Submits Briefing Package to Guide Upcoming FDA Meeting

Adial Pharmaceuticals Advances Toward Phase 3 Development for AD04

GlobeNewswire

2 months ago

Adial Pharmaceuticals Advances Toward Phase 3 Development for AD04

EXCLUSIVE: Adial Pharmaceuticals Lead Candidate For Alcohol Use Disorder Advances Toward Phase 3 Trial

Benzinga

2 months ago

EXCLUSIVE: Adial Pharmaceuticals Lead Candidate For Alcohol Use Disorder Advances Toward Phase 3 Trial

Adial Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

GlobeNewswire

3 months ago

Adial Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

Adial Pharmaceuticals Receives Milestone Payment from Adovate Following Initiation of Phase 1 Study

GlobeNewswire

3 months ago

Adial Pharmaceuticals Receives Milestone Payment from Adovate Following Initiation of Phase 1 Study

Adial Pharmaceuticals Granted End of Phase 2 Meeting from the U.S. Food and Drug Administration

GlobeNewswire

3 months ago

Adial Pharmaceuticals Granted End of Phase 2 Meeting from the U.S. Food and Drug Administration

EXCLUSIVE: Adial Pharmaceuticals Secures FDA End of Phase 2 Meeting Request To Discuss Upcoming Clinical Development Plan For Lead Program

Benzinga

3 months ago

EXCLUSIVE: Adial Pharmaceuticals Secures FDA End of Phase 2 Meeting Request To Discuss Upcoming Clinical Development Plan For Lead Program

Adial Pharmaceuticals Announces a Warrant Inducement Transaction for $2.75 Million in Gross Proceeds

GlobeNewswire

3 months ago

Adial Pharmaceuticals Announces a Warrant Inducement Transaction for $2.75 Million in Gross Proceeds

Adial Pharmaceuticals Expands Intellectual Property Portfolio with New U.S. Patent Granted for Genetic-Based Treatment of Alcohol and Opioid Use Disorders

GlobeNewswire

3 months ago

Adial Pharmaceuticals Expands Intellectual Property Portfolio with New U.S. Patent Granted for Genetic-Based Treatment of Alcohol and Opioid Use Disorders

EXCLUSIVE: Adial Pharmaceuticals Expands Patent Portfolio With New US Patent For Lead Drug For Alcohol And Opioid Use Disorders

Benzinga

3 months ago

EXCLUSIVE: Adial Pharmaceuticals Expands Patent Portfolio With New US Patent For Lead Drug For Alcohol And Opioid Use Disorders

Adial Pharmaceuticals Reports 2024 Fiscal Year Financial Results and Provides Business Update

GlobeNewswire

5 months ago

Adial Pharmaceuticals Reports 2024 Fiscal Year Financial Results and Provides Business Update

Adial Pharmaceuticals Receives Positive Response from FDA Meeting Regarding Proposed In Vitro Bridging Strategy for AD04

GlobeNewswire

6 months ago

Adial Pharmaceuticals Receives Positive Response from FDA Meeting Regarding Proposed In Vitro Bridging Strategy for AD04

EXCLUSIVE: After FDA Response, Adial Starts Manufacturing Clinical Supplies For Upcoming Phase 3 Program Of Lead Candidate For Alcohol Use Disorder

Benzinga

6 months ago

EXCLUSIVE: After FDA Response, Adial Starts Manufacturing Clinical Supplies For Upcoming Phase 3 Program Of Lead Candidate For Alcohol Use Disorder

Adial Pharmaceuticals Granted New U.S. Patent Expanding Coverage of its Genetic-Based Approach to Treating and Diagnosing Alcohol Use Disorder and Other Drug Dependencies

GlobeNewswire

6 months ago

Adial Pharmaceuticals Granted New U.S. Patent Expanding Coverage of its Genetic-Based Approach to Treating and Diagnosing Alcohol Use Disorder and Other Drug Dependencies

Adial Pharmaceuticals Awarded New U.S. Patent Covering Genotype-Specific Treatment of Opioid-Related Disorders

GlobeNewswire

6 months ago

Adial Pharmaceuticals Awarded New U.S. Patent Covering Genotype-Specific Treatment of Opioid-Related Disorders

EXCLUSIVE: Adial Pharmaceuticals Secures New US Patent Covering Genotype-Specific Treatment of Opioid-Related Disorders

Benzinga

6 months ago

EXCLUSIVE: Adial Pharmaceuticals Secures New US Patent Covering Genotype-Specific Treatment of Opioid-Related Disorders

Adial Pharmaceuticals Announces Positive Clinical Study Results from the AD04-103 Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

GlobeNewswire

6 months ago

Adial Pharmaceuticals Announces Positive Clinical Study Results from the AD04-103 Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

EXCLUSIVE: Adial Pharmaceuticals Reveals Positive Pharmacokinetics Study Results Of AD04 For Alcohol Use Disorder

Benzinga

6 months ago

EXCLUSIVE: Adial Pharmaceuticals Reveals Positive Pharmacokinetics Study Results Of AD04 For Alcohol Use Disorder

MT Newswires

8 months ago

Adial Pharmaceuticals Files Preliminary Prospectus for Secondary Stock Sale

Adial Pharmaceuticals Granted Key U.S. Patent for the Treatment of Alcohol and Drug Dependence Based on Expanded Genotype Combinations

GlobeNewswire

8 months ago

Adial Pharmaceuticals Granted Key U.S. Patent for the Treatment of Alcohol and Drug Dependence Based on Expanded Genotype Combinations

EXCLUSIVE: Adial Pharmaceuticals' Lead Drug Secures Key US Patent For Alcohol Dependence Based on Expanded Genotype Combinations

Benzinga

8 months ago

EXCLUSIVE: Adial Pharmaceuticals' Lead Drug Secures Key US Patent For Alcohol Dependence Based on Expanded Genotype Combinations

PR Newswire

8 months ago

From kitchen waste to jet fuel: China's amazing energy solutions

2 Social Security Cost-of-Living Adjustment (COLA) Changes Retirees Really Want to See

Motley Fool

8 months ago

2 Social Security Cost-of-Living Adjustment (COLA) Changes Retirees Really Want to See

Global Times: Exploring China's treasure trove of ethnic cultures

PR Newswire

8 months ago

Global Times: Exploring China's treasure trove of ethnic cultures

Sosandar First Half 2025 Earnings: UK£0.003 loss per share (vs UK£0.005 loss in 1H 2024)

Simply Wall St.

8 months ago

Sosandar First Half 2025 Earnings: UK£0.003 loss per share (vs UK£0.005 loss in 1H 2024)

Adler Group Third Quarter 2024 Earnings: EPS: €12.99 (vs €1.42 loss in 3Q 2023)

Simply Wall St.

8 months ago

Adler Group Third Quarter 2024 Earnings: EPS: €12.99 (vs €1.42 loss in 3Q 2023)

Epwin Group's (LON:EPWN) investors will be pleased with their respectable 60% return over the last year

Simply Wall St.

8 months ago

Epwin Group's (LON:EPWN) investors will be pleased with their respectable 60% return over the last year

Renew Holdings Full Year 2024 Earnings: EPS: UK£0.66 (vs UK£0.60 in FY 2023)

Simply Wall St.

8 months ago

Renew Holdings Full Year 2024 Earnings: EPS: UK£0.66 (vs UK£0.60 in FY 2023)

Floods displace 122,000 people in Malaysia

AFP

8 months ago

Floods displace 122,000 people in Malaysia

Adial Pharmaceuticals (ADIL) Upgraded to Buy: Here's What You Should Know

Zacks

9 months ago

Adial Pharmaceuticals (ADIL) Upgraded to Buy: Here's What You Should Know

Adial Pharmaceuticals Announces Positive Topline Results from the AD04-103 Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

GlobeNewswire

9 months ago

Adial Pharmaceuticals Announces Positive Topline Results from the AD04-103 Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

EXCLUSIVE: Adial Pharmaceuticals Reveals Topline Results From Pharmacokinetics Study Of AD04 For Alcohol Use Disorder

Benzinga

9 months ago

EXCLUSIVE: Adial Pharmaceuticals Reveals Topline Results From Pharmacokinetics Study Of AD04 For Alcohol Use Disorder

Adial Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire

9 months ago

Adial Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

Adial Pharmaceuticals Appoints Vinay Shah as Chief Financial Officer

GlobeNewswire

9 months ago

Adial Pharmaceuticals Appoints Vinay Shah as Chief Financial Officer

Adial Pharmaceuticals to Present at the 2024 ThinkEquity Conference

GlobeNewswire

10 months ago

Adial Pharmaceuticals to Present at the 2024 ThinkEquity Conference

MT Newswires

10 months ago

Adial Pharmaceuticals Gets US Patent Allowance for Expanded Genotypes in Addiction Treatment

Adial Pharmaceuticals Receives Notice of Allowance for U.S. Patent Covering Expanded Genotype Combinations Identified Using the Company’s Genetic Diagnostic for Addiction Treatment

GlobeNewswire

10 months ago

Adial Pharmaceuticals Receives Notice of Allowance for U.S. Patent Covering Expanded Genotype Combinations Identified Using the Company’s Genetic Diagnostic for Addiction Treatment

EXCLUSIVE: Adial Pharmaceuticals Secures Additional US Patent Expanding Intellectual Property Protection Around Its Alcohol Use Disorder Candidate

Benzinga

10 months ago

EXCLUSIVE: Adial Pharmaceuticals Secures Additional US Patent Expanding Intellectual Property Protection Around Its Alcohol Use Disorder Candidate

Adial Pharmaceuticals Commends the National Institute on Alcohol Abuse and Alcoholism's New Definition of Recovery

GlobeNewswire

10 months ago

Adial Pharmaceuticals Commends the National Institute on Alcohol Abuse and Alcoholism's New Definition of Recovery

Adial Pharmaceuticals Announces Database Lock in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

GlobeNewswire

a year ago

Adial Pharmaceuticals Announces Database Lock in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

Adial Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

GlobeNewswire

a year ago

Adial Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Adial Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire

a year ago

Adial Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

MT Newswires

a year ago

Adial Signs Deal With Boudicca to Advance Regulatory Strategy for Companion Diagnostic Genetic Test

Adial Pharmaceuticals Signs Agreement with Boudicca Dx to Advance Regulatory Strategy for Companion Diagnostic Genetic Test for AD04

GlobeNewswire

a year ago

Adial Pharmaceuticals Signs Agreement with Boudicca Dx to Advance Regulatory Strategy for Companion Diagnostic Genetic Test for AD04

EXCLUSIVE: Adial Pharmaceuticals Advances Regulatory Strategy For Companion Diagnostic Genetic Test For Its Lead Program For Alcohol Use Disorder

Benzinga

a year ago

EXCLUSIVE: Adial Pharmaceuticals Advances Regulatory Strategy For Companion Diagnostic Genetic Test For Its Lead Program For Alcohol Use Disorder

Adial Pharmaceuticals Announces Last Patient Dosed in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

GlobeNewswire

a year ago

Adial Pharmaceuticals Announces Last Patient Dosed in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

EXCLUSIVE: Adial Pharmaceuticals' Last Patient Dosed in Pharmacokinetics Study of AD04 For Alcohol Use Disorder, Data Expected In Q4

Benzinga

a year ago

EXCLUSIVE: Adial Pharmaceuticals' Last Patient Dosed in Pharmacokinetics Study of AD04 For Alcohol Use Disorder, Data Expected In Q4

Adial Pharmaceuticals Files New Patent Application to Protect Core Assets and Extend IP Exclusivity on Core Technology to 2044

GlobeNewswire

a year ago

Adial Pharmaceuticals Files New Patent Application to Protect Core Assets and Extend IP Exclusivity on Core Technology to 2044

MT Newswires

a year ago

Sector Update: Health Care Stocks Edge Higher Late Afternoon

MT Newswires

a year ago

Sector Update: Health Care

MT Newswires

a year ago

Top Midday Gainers

Adial Pharmaceuticals Advances to Second Cohort in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

GlobeNewswire

a year ago

Adial Pharmaceuticals Advances to Second Cohort in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

EXCLUSIVE: Adial Pharmaceuticals Moves Forward To Second Cohort In Pharmacokinetics Study of AD04 For Alcohol Use Disorder

Benzinga

a year ago

EXCLUSIVE: Adial Pharmaceuticals Moves Forward To Second Cohort In Pharmacokinetics Study of AD04 For Alcohol Use Disorder

Adial Pharmaceuticals Announces Publication in Leading Peer-Reviewed Journal Supporting the Potential Efficacy of AD04 as a Precision Medicine for the Treatment of Alcohol Use Disorder

GlobeNewswire

a year ago

Adial Pharmaceuticals Announces Publication in Leading Peer-Reviewed Journal Supporting the Potential Efficacy of AD04 as a Precision Medicine for the Treatment of Alcohol Use Disorder

EXCLUSIVE: Adial Pharmaceuticals Announces Publication In Journal Supporting the Potential Efficacy Of AD04 For Alcohol Use Disorder

Benzinga

a year ago

EXCLUSIVE: Adial Pharmaceuticals Announces Publication In Journal Supporting the Potential Efficacy Of AD04 For Alcohol Use Disorder

MicroCap Rodeo’s Spring into Summer Conference, June 6th 2024 - 25 Presenting Companies

ACCESSWIRE

a year ago

MicroCap Rodeo’s Spring into Summer Conference, June 6th 2024 - 25 Presenting Companies

Adial Pharmaceuticals Achieves Important Milestone of First Patient Dosed in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

GlobeNewswire

a year ago

Adial Pharmaceuticals Achieves Important Milestone of First Patient Dosed in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

EXCLUSIVE: Adial Pharmaceuticals Starts Patient Dosing In Pharmacokinetics Study Of AD04 For Alcohol Use Disorder

Benzinga

a year ago

EXCLUSIVE: Adial Pharmaceuticals Starts Patient Dosing In Pharmacokinetics Study Of AD04 For Alcohol Use Disorder

Adial CEO to Present at the Spring MicroCap Rodeo Conference on June 6th

GlobeNewswire

a year ago

Adial CEO to Present at the Spring MicroCap Rodeo Conference on June 6th

Adial Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire

a year ago

Adial Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update

EXCLUSIVE: Alcohol Disorder Focused Adial Pharmaceuticals Secures US Patent

Benzinga

a year ago

EXCLUSIVE: Alcohol Disorder Focused Adial Pharmaceuticals Secures US Patent

Adial Pharmaceuticals Granted Key Patent from the United States Patent and Trademark Office

GlobeNewswire

a year ago

Adial Pharmaceuticals Granted Key Patent from the United States Patent and Trademark Office

Adial Pharmaceuticals Announces Peer-Reviewed Publication Highlighting Promising Safety Data and High Patient Compliance in a Clinical Trial of AD04 as a Potential Treatment for Alcohol Use Disorder

GlobeNewswire

a year ago

Adial Pharmaceuticals Announces Peer-Reviewed Publication Highlighting Promising Safety Data and High Patient Compliance in a Clinical Trial of AD04 as a Potential Treatment for Alcohol Use Disorder

Adial Pharmaceuticals Reports 2023 Fiscal Year Financial Results and Provides Business Update

GlobeNewswire

a year ago

Adial Pharmaceuticals Reports 2023 Fiscal Year Financial Results and Provides Business Update

Is Masimo (MASI) Outperforming Other Medical Stocks This Year?

Zacks

a year ago

Is Masimo (MASI) Outperforming Other Medical Stocks This Year?

Adial Pharmaceuticals Announces Exercise of Warrants for $3.5 Million Gross Proceeds

GlobeNewswire

a year ago

Adial Pharmaceuticals Announces Exercise of Warrants for $3.5 Million Gross Proceeds

EXCLUSIVE: Adial Pharmaceuticals Secures New US Patent Covering Lead Product For Alcohol Use Disorder

Benzinga

a year ago

EXCLUSIVE: Adial Pharmaceuticals Secures New US Patent Covering Lead Product For Alcohol Use Disorder

Adial Pharmaceuticals Awarded New Patent from the United States Patent and Trademark Office

GlobeNewswire

a year ago

Adial Pharmaceuticals Awarded New Patent from the United States Patent and Trademark Office

Adial Pharmaceuticals to Present at the Winter Wrap-Up MicroCap Rodeo Conference on February 20

ACCESSWIRE

a year ago

Adial Pharmaceuticals to Present at the Winter Wrap-Up MicroCap Rodeo Conference on February 20

Adial Pharmaceuticals Awarded New Patent Notice of Allowance from the United States Patent and Trademark Office

GlobeNewswire

a year ago

Adial Pharmaceuticals Awarded New Patent Notice of Allowance from the United States Patent and Trademark Office

Red Cat Continues Global Expansion Efforts with Introduction to Middle East Market

GlobeNewswire

2 years ago

Red Cat Continues Global Expansion Efforts with Introduction to Middle East Market

Ford And GM Expect EVs Will Stall For A While, But Stellantis, Tesla And Worksport Don't Think That Will Be The Case

Benzinga

2 years ago

Ford And GM Expect EVs Will Stall For A While, But Stellantis, Tesla And Worksport Don't Think That Will Be The Case

Lexaria's Submits Investigational New Drug Application

ACCESSWIRE

2 years ago

Lexaria's Submits Investigational New Drug Application

Worksport Subsidiary Terravis Energy Starts To Build Heat Pump Supply Chain

GlobeNewswire

2 years ago

Worksport Subsidiary Terravis Energy Starts To Build Heat Pump Supply Chain

OneMedNet Announces Participation as an Exhibitor at the 15ᵗʰ Annual SCOPE Summit

GlobeNewswire

2 years ago

OneMedNet Announces Participation as an Exhibitor at the 15ᵗʰ Annual SCOPE Summit

Clean Energy Technologies Continues Normal Operations Among Stock Volatility

GlobeNewswire

2 years ago

Clean Energy Technologies Continues Normal Operations Among Stock Volatility

eFFECTOR Therapeutics Announces $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

GlobeNewswire

2 years ago

eFFECTOR Therapeutics Announces $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Lexaria Releases Annual Letter from the CEO

ACCESSWIRE

2 years ago

Lexaria Releases Annual Letter from the CEO

bioAffinity Technologies Announces Award of Therapeutic Patent for Treatment of Cancer

Business Wire

2 years ago

bioAffinity Technologies Announces Award of Therapeutic Patent for Treatment of Cancer

NEXGEL to Present at The Microcap Conference, January 30th through February 1st

GlobeNewswire

2 years ago

NEXGEL to Present at The Microcap Conference, January 30th through February 1st

Adial Announces Appointment of Tony Goodman as Chief Operating Officer

GlobeNewswire

2 years ago

Adial Announces Appointment of Tony Goodman as Chief Operating Officer

1,300 E-JEEPNEY ORDER COMMITMENTS IN THE PHILIPPINES FOR TEMBO FRANCISCO MOTORS JOINT VENTURE

PR Newswire

2 years ago

1,300 E-JEEPNEY ORDER COMMITMENTS IN THE PHILIPPINES FOR TEMBO FRANCISCO MOTORS JOINT VENTURE

FinWise Bancorp to Host Fourth Quarter and Full Year 2023 Webcast and Conference Call on Monday, January 29, 2024

GlobeNewswire

2 years ago

FinWise Bancorp to Host Fourth Quarter and Full Year 2023 Webcast and Conference Call on Monday, January 29, 2024

Save Foods: Nitrousink Files US Patent Application for Reducing Emissions of Nitrous Oxide in Wheat

GlobeNewswire

2 years ago

Save Foods: Nitrousink Files US Patent Application for Reducing Emissions of Nitrous Oxide in Wheat

Arqit announces reseller agreement with Phalanx

GlobeNewswire

2 years ago

Arqit announces reseller agreement with Phalanx

NEXGEL Subsidiary, CG Converting and Packaging, Begins 12,000 Square Foot Expansion of Texas Facility to Support the Expected Growth in Product Demand in 2024

GlobeNewswire

2 years ago

NEXGEL Subsidiary, CG Converting and Packaging, Begins 12,000 Square Foot Expansion of Texas Facility to Support the Expected Growth in Product Demand in 2024

eFFECTOR Therapeutics to Host Virtual Investor R&D Day on January 24, 2024

GlobeNewswire

2 years ago

eFFECTOR Therapeutics to Host Virtual Investor R&D Day on January 24, 2024

Ekso Bionics Launches GaitCoach Software for EksoNR

GlobeNewswire

2 years ago

Ekso Bionics Launches GaitCoach Software for EksoNR

Allurion Announces Preliminary Fourth Quarter and Full Year 2023 Results and Provides 2024 Outlook

Business Wire

2 years ago

Allurion Announces Preliminary Fourth Quarter and Full Year 2023 Results and Provides 2024 Outlook

Genprex Provides Business Update and Outlook for 2024

PR Newswire

2 years ago

Genprex Provides Business Update and Outlook for 2024

Business Wire

2 years ago

Boxlight Corporation Board of Directors Announces Leadership Changes

Ekso Bionics Reports Certain Preliminary Fourth Quarter and Full Year 2023 Financial Results

GlobeNewswire

2 years ago

Ekso Bionics Reports Certain Preliminary Fourth Quarter and Full Year 2023 Financial Results

Business Wire

2 years ago

Boxlight Announces Licensed EDLA MimioPro G Interactive Flat Panel with Google Certified Professional Development for Educators

GeoVax Announces Issuance of Malaria Vaccine Patent

GlobeNewswire

2 years ago

GeoVax Announces Issuance of Malaria Vaccine Patent

2023 Will Go Down As The Year Pharma Showed Its Determination To Beat Cancer

Benzinga

2 years ago

2023 Will Go Down As The Year Pharma Showed Its Determination To Beat Cancer

Trust Stamp has partnered with Scurid to deliver highly secure, AI-powered in-field authentication for seamless human-machine interaction

GlobeNewswire

2 years ago

Trust Stamp has partnered with Scurid to deliver highly secure, AI-powered in-field authentication for seamless human-machine interaction

BrainStorm Granted Patents for Allogeneic Exosome Platform-Product in Neurological Disorder Treatments

PR Newswire

2 years ago

BrainStorm Granted Patents for Allogeneic Exosome Platform-Product in Neurological Disorder Treatments

Share on Social Networks: